DLA Piper advises SPE Capital on the sale of Amanys Pharma to Laprophan

DLA Piper has advised SPE Capital on the sale of Amanys Pharma to Laprophan, a pioneering pharmaceutical company in Morocco.

Amanys Pharma is a pharmaceutical production and distribution group specialized in the production of antibiotics for the general public and the distribution of niche products for the hospital sector.

Laprophan, which has been a pioneer in the Moroccan pharmaceutical industry for more than 70 years, hasalso benefited from an investment by a consortium of investors. These include Mediterrania Capital Partners (MCP), Proparco, DEG, and FMO. The sale of Amanys to Laprophan will allow both companies to utlise synergies to better meet the growing health needs in Morocco and the continent.

The sale is subject to obtaining the usual required regulatory approvals.

The DLA Piper team advising on the transaction and was led out of the Casablanca office by Corporate Partner, Benoit de Monval and was supported by Associate Ghita Moussaid.